No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Mizuho Securities Maintains Athira(ATHA.US) With Hold Rating
BTIG Maintains Athira(ATHA.US) With Hold Rating
Athira Pharma's Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating Maintained
Athira Pharma's 2024 Financial Results and Pipeline Progress
Athira Pharma FY 2024 GAAP EPS $(2.52) Beats $(2.54) Estimate
Athira | 10-K: FY2024 Annual Report